Mirati Therapeutics, Inc. announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015. Data from the study titled, a First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD516, in Patients with Advanced Solid Tumors will be presented during the Early Drug Development poster session on September 27, 2015 from 4:45 – 6:45 PM CEST or 7:45 – 9:45 AM PDT at the Messe Wien Exhibition and Congress Centre, Hall C. MGCD516 is a potent, orally bio-available inhibitor of key pathways that drive tumor growth. Specifically, MGCD516 targets driver mutations including RET, Trk and DDR gene alterations, which occur most often in patients with non-small cell lung cancer.

MGCD516 is a tyrosine kinase inhibitor that has demonstrated potent inhibition of a closely related spectrum of tyrosine kinases including RET, Trk and DDR, which are key regulators of signaling pathways that lead to cell growth, survival and tumor progression. These kinases and their key regulatory pathways are genetically altered in multiple cancer indications and act as oncogenic drivers that promote cancer development and progression in solid tumors, including non-small cell lung cancer. MGCD516 is in a Phase 1 dose escalation study in advanced solid tumors with an initial focus on NSCLC.

Mirati retains worldwide rights to MGCD516.